US 12,129,266 B2
Substituted pyrazolo[1,5-a]pyridine compound, composition containing the same and use thereof
Yihan Wang, Guangdong (CN); and Xingye Ren, Guangdong (CN)
Assigned to Shenzhen TargetRx, Inc., Shenzhen (CN)
Appl. No. 17/299,999
Filed by Shenzhen TargetRx, Inc., Guangdong (CN)
PCT Filed Dec. 3, 2019, PCT No. PCT/CN2019/122674
§ 371(c)(1), (2) Date Jun. 4, 2021,
PCT Pub. No. WO2020/114388, PCT Pub. Date Jun. 11, 2020.
Claims priority of application No. 201811488548.X (CN), filed on Dec. 6, 2018; and application No. 201811527134.3 (CN), filed on Dec. 13, 2018.
Prior Publication US 2022/0017539 A1, Jan. 20, 2022
Int. Cl. C07D 519/00 (2006.01); C07D 471/04 (2006.01)
CPC C07D 519/00 (2013.01) [C07D 471/04 (2013.01)] 20 Claims
 
1. A compound of formula (I), or a tautomer, stereoisomer, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof:

OG Complex Work Unit Chemistry
wherein,
Y is selected from the group consisting of CH and N, which is optionally substituted by deuterium, halogen or trifluoromethyl;
W is CR9R10;
R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are each independently selected from the group consisting of hydrogen and deuterium;
Y1, Y2, Y3, Y4, Y5, Y6, Y7 and Y8 are each independently selected from the group consisting of hydrogen, deuterium, halogen and trifluoromethyl;
X is selected from the group consisting of CH3, CD3, CHD2 and CH2D;
Z is selected from the group consisting of:

OG Complex Work Unit Chemistry
 which is optionally substituted by 1, 2, 3, 4, 5, 6, 7, 8 or 9 deuterium;
*represents the bond connected to the core;
provided that the above compound has at least one deuterium atom.